SEC Comment Letter for Black Bird Biotech, Inc. (BBBT) (CIK 0001409999) — Sep 21, 2021

Black Bird Biotech, Inc. (BBBT) (CIK 0001409999)
Date: Sept. 21, 2021 · CIK: 0001409999 · Accession: 0000000000-21-011446

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 024-11621

Date

September 21, 2021

Author

Division of Corporation Finance

Form

UPLOAD

Company

Black Bird Biotech, Inc. (BBBT) (CIK 0001409999)

Letter

United States securities and exchange commission logo September 21, 2021 Eric Newlan Secretary, Director & Vice President Black Bird Biotech, Inc. 3505 Yucca Drive, Suite 104 Flower Mound, Texas 75028 Re:Black Bird Biotech, Inc. Post-Qualification Amendment No. 1 to Form 1-A Filed September 16, 2021 File No. 024-11621 Dear Mr. Newlan: This is to advise you that we do not intend to review your amendment. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Gregory Herbers at 202-551-8028 with any questions.

Sincerely,
Division of Corporation Finance
Office of Manufacturing

Show Raw Text

United States securities and exchange commission logo
September 21, 2021
Eric Newlan
Secretary, Director & Vice President
Black Bird Biotech, Inc.
3505 Yucca Drive, Suite 104
Flower Mound, Texas 75028
Re:Black Bird Biotech, Inc.
Post-Qualification Amendment No. 1 to Form 1-A
Filed September 16, 2021
File No. 024-11621
Dear Mr. Newlan:
            This is to advise you that we do not intend to review your amendment.
            We will consider qualifying your offering statement at your request. If a participant in
your offering is required to clear its compensation arrangements with FINRA, please have
FINRA advise us that it has no objections to the compensation arrangements prior to
qualification.
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            Please contact Gregory Herbers at 202-551-8028 with any questions.

Sincerely,
Division of Corporation Finance
Office of Manufacturing

SecProbe.io